Friday Apr 4
Sorrento Therapeutics Announces Key Presentation on Cynviloq at the...
Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq and Abraxane pharmacokinetics from animal studies.
Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane
Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer.
Reports Outline Paclitaxel Therapy Study Findings from University of Buenos Aires
PTX-loaded poly -alpha tocopheryl polyethylene glycol 1000 succinate NPs were prepared using three different techniques: by nanoprecipitation , by emulsion-solvent evaporation homogenized with an Ultra-Turrax and by emulsion-solvent evaporation homogenized with an ultra-sonicator ."
Cortice Announces Enrollment of a Phase 2 Trial Evaluating TPI 287...
Cortice Biosciences announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy of the Company's lead drug candidate, TPI 287, in combination with standard-of-care Avastin for treatment of patients with recurrent glioblastoma that has progressed following Avastin treatment ... (more)
Chemical & Engineering News
ACS Meeting News: Taking Cues From Nature En Route To Taxol
No one is better than nature at making the cancer drug paclitaxel . Cumulatively, chemists have been able to produce only small amounts of the stuff, but a plant cell fermentation process can churn out metric tons of the compound.